Free Trial

Healthcare Stocks List

This page shows information about the 50 largest healthcare sector stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie and Merck & Co., Inc..

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$1,211.08 +44.57 (+3.82%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$1,227.70 +16.62 (+1.37%)
As of 05:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • Eli Lilly and Co recently reported strong third-quarter results, beating consensus estimates with earnings per share of $8.38 against an expected $6.40 and revenue of $22.97 billion, which exceeded the $20.82 billion forecast, demonstrating robust demand for its diabetes and obesity treatments.
  • The company has received positive analyst sentiment, with Royal Bank of Canada reaffirming an "Outperform" rating and setting a price target of $1,500.00, which suggests a potential upside of approximately 26.7% from the current stock price of $1,183.51.
  • Eli Lilly and Co is likely to raise its full-year revenue outlook due to strong sales momentum in its diabetes and weight-loss drug segments, indicating that the company expects continued high demand for its GLP-1 products in the coming quarters.

Cons of Eli Lilly and Company

  • The stock has pulled back approximately 8% from its recent highs, with some analysts suggesting that taking profits could make sense ahead of 2027 as shares have modestly underperformed the S&P 500 in 2026.
  • Eli Lilly and Co is facing intensifying competition from Novo Nordisk, which has seen its stock decline due to pricing pressure and a lack of near-term growth visibility, potentially impacting Eli Lilly and Co's market share in the obesity treatment space.
  • The company is dealing with a black market for its new obesity drug retatrutide even before its official launch, as illicit sellers are offering the drug online, which could undermine pricing power and brand integrity.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$1.10 trillion
P/E Ratio
40.64
Consensus Rating
Moderate Buy
Consensus Price Target
$1,313.43 (+8.5% Upside)
Volume
3.16 million shares
Average Volume
2.23 million shares
Today's Range
$1,174.24
▼
$1,216.71
50-Day Range
$1,115.53
▼
$1,280.62
52-Week Range
$783.85
▼
$1,292.65
Dividend Yield
0.59%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$253.49 +4.88 (+1.96%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$257.53 +4.04 (+1.59%)
As of 05:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • Johnson & Johnson recently reported third-quarter adjusted earnings per share of $2.59, which exceeded the consensus estimate of $2.53, while revenue increased 5.9% year over year to $25.4 billion, demonstrating strong fundamental performance in its Innovative Medicine segment.
  • Management raised its full-year 2026 outlook to revenue of $101.0 billion to $101.4 billion and adjusted earnings per share of $11.05 to $11.15, signaling confidence that pharmaceutical momentum is successfully offsetting near-term pressure in the device market.
  • The company declared a quarterly dividend of $1.34 per share, which annualizes to $5.36 and provides a yield of approximately 2.1% to 2.2%, offering a consistent income stream for investors despite the current stock price of $253.49.

Cons of Johnson & Johnson

  • MedTech segment growth was only about 2.5% operationally and missed expectations, particularly in cardiovascular and surgery businesses outside the United States, raising concerns about the growth trajectory of this division amid Middle East-related budget disruptions.
  • Reported third-quarter GAAP earnings per share fell to approximately $0.09 due to significant charges tied to the proposed talc litigation resolution, the Firefly Bio acquisition, and the Sail Biomedicines collaboration, which overshadowed the adjusted earnings beat.
  • Several analysts have recently lowered their price targets and earnings estimates, such as Royal Bank of Canada reducing its target from $290 to $280 and Erste Group lowering its 2027 earnings per share estimate, signaling that Wall Street sees less near-term upside despite generally constructive ratings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$599.12 billion
P/E Ratio
38.41
Consensus Rating
Moderate Buy
Consensus Price Target
$273.61 (+7.9% Upside)
Volume
9.65 million shares
Average Volume
7.45 million shares
Today's Range
$248.50
▼
$253.94
50-Day Range
$248.90
▼
$278.66
52-Week Range
$184.66
▼
$281.07
Dividend Yield
2.16%
AbbVie stock logo

3. AbbVie NYSE:ABBV

$283.58 +9.22 (+3.36%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$286.25 +2.67 (+0.94%)
As of 05:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • AbbVie reported strong third-quarter 2026 results on July 31, 2026, beating analyst expectations with earnings per share of $3.65 compared to a consensus estimate of $3.61, while revenue reached $16.99 billion, exceeding the $16.80 billion forecast and marking a 10.2% year-over-year increase.
  • New Phase 3 AFFIRM data presented in October 2026 demonstrated that subcutaneous SKYRIZI improved clinical and endoscopic outcomes versus placebo in adults with moderately to severely active Crohn’s disease, potentially supporting regulatory review for a more convenient induction option and strengthening the company's post-Humira immunology growth story.
  • The stock is trading at $283.58 as of October 14, 2026, which is near its 52-week high of $285.40, reflecting a significant upward trend from its 52-week low of $190.75 and indicating strong recent momentum and investor confidence.

Cons of AbbVie

  • The company has a high P/E ratio of 80.11, which is significantly elevated compared to many peers, suggesting that the stock price is expensive relative to its current earnings and may leave little room for error if growth slows.
  • AbbVie's payout ratio is 195.48%, meaning the company is paying out more in dividends than it is earning in net income, which could raise concerns about the sustainability of the dividend yield of 2.46% if profitability does not improve.
  • Some analysts and investors are comparing AbbVie unfavorably with Sanofi, whose upgraded 2026 outlook, Dupixent growth, and lower valuation may offer a more attractive risk-reward profile, potentially diverting capital away from AbbVie.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$484.74 billion
P/E Ratio
80.11
Consensus Rating
Moderate Buy
Consensus Price Target
$277.18 (-2.3% Downside)
Volume
5.62 million shares
Average Volume
4.65 million shares
Today's Range
$275.97
▼
$285.40
50-Day Range
$243.64
▼
$283.58
52-Week Range
$190.75
▼
$285.40
Dividend Yield
2.52%
Merck & Co., Inc. stock logo

4. Merck & Co., Inc. NYSE:MRK

$147.47 +5.49 (+3.86%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$150.42 +2.95 (+2.00%)
As of 05:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • Merck is set to present first-time Phase 3 results from three pivotal oncology trials at the upcoming ESMO 2026 conference, which could significantly boost investor confidence in the company's pipeline and its ability to generate growth beyond its flagship Keytruda drug.
  • The stock is currently trading at $147.47, reflecting a strong upward momentum with a 3.6% jump in recent trading, which suggests positive market sentiment ahead of the company's third-quarter earnings report expected in the coming weeks.
  • Merck offers a dividend yield of 2.34%, providing a steady income stream for investors, with the company recently declaring a quarterly dividend of $0.85 per share that was paid on October 7th.

Cons of Merck & Co., Inc.

  • Merck faces significant competitive risks, including the looming threat of biosimilar competition for Keytruda in 2028-2029, which could erode the drug's market share and revenue contribution in the future.
  • The company's valuation is elevated, with a P/E ratio of 117.97, which may limit upside potential if earnings growth does not meet high expectations, and the firm has reported a negative operating margin in recent periods.
  • Jefferies has cut its peak-sales forecast for Merck's experimental eye drug remigromig by 60% following efficacy and safety concerns in recent trials, highlighting the risks associated with the company's pipeline development.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$350.29 billion
P/E Ratio
117.97
Consensus Rating
Moderate Buy
Consensus Price Target
$151.92 (+3.0% Upside)
Volume
9.80 million shares
Average Volume
9.93 million shares
Today's Range
$142.66
▼
$148.16
50-Day Range
$128.27
▼
$156.54
52-Week Range
$82.01
▼
$156.92
Dividend Yield
2.34%
UnitedHealth Group stock logo

5. UnitedHealth Group NYSE:UNH

$396.02 +18.26 (+4.83%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$398.50 +2.48 (+0.63%)
As of 05:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • UnitedHealth Group is currently trading at $377.98, which is significantly below the consensus price target of $456.56, suggesting substantial upside potential as analysts maintain a Moderate Buy rating based on recent data.
  • The company demonstrated strong earnings momentum by reporting $6.38 in earnings per share for the quarter ended July 16, 2026, which exceeded the consensus estimate of $4.94 by a wide margin, indicating effective cost controls and operational efficiency.
  • Investors can benefit from a dividend yield of 2.45%, supported by a recent quarterly dividend payment of $2.32 per share, providing a steady income stream while the company maintains a payout ratio of 59.72%.

Cons of UnitedHealth Group

  • Revenue growth remains subdued, with the most recent quarter showing only a 0.4% year-over-year increase, which may limit the company's ability to drive top-line expansion despite margin improvements.
  • Medicare Advantage star-rating changes have negatively impacted UnitedHealth Group, with J.P. Morgan estimating that the company's 4-star enrollment share has fallen to 67%, potentially affecting reimbursement rates and competitive positioning against rivals like Humana.
  • Some analysts, such as TD Cowen, have lowered their price targets to $402, reflecting continued caution regarding the sustainability of margin repair and the company's ability to manage medical costs effectively.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$339.08 billion
P/E Ratio
22.62
Consensus Rating
Moderate Buy
Consensus Price Target
$461.83 (+16.6% Upside)
Volume
7.76 million shares
Average Volume
5.53 million shares
Today's Range
$382.29
▼
$396.44
50-Day Range
$365.24
▼
$408.70
52-Week Range
$255.96
▼
$461.62
Dividend Yield
2.46%
Novartis stock logo

6. Novartis NYSE:NVS

$146.94 +4.53 (+3.18%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$149.28 +2.35 (+1.60%)
As of 05:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • Novartis AG recently secured FDA approval for Rhapsido (remibrutinib) for symptomatic dermographism, marking the first treatment for this condition and expanding the drug's commercial potential beyond chronic spontaneous urticaria, which is a significant catalyst for growth in the immunology sector.
  • The company reported positive Phase III results for remibrutinib in relapsing multiple sclerosis, suggesting a broader therapeutic application that could drive future revenue, with an investor call scheduled for October 23, 2026, to discuss this program further.
  • Novartis AG demonstrated strong financial performance in its most recent quarter, reporting earnings per share of $2.41 and revenue of $14.95 billion, with a net margin of 23.29% and a return on equity of 38.56%, indicating robust profitability and efficient capital management.

Cons of Novartis

  • Erste Group Bank recently cut its FY2027 earnings per share estimate for Novartis AG to $9.80 from $9.81, signaling potential concerns about future earnings growth, although the consensus estimate remains at $8.91 per share.
  • The stock has a price-to-earnings ratio of 22.16, which is relatively high compared to some peers, and the consensus rating from analysts is "Hold" with a target price of $145.60, suggesting limited upside potential from the current price of $146.94.
  • Novartis AG has a debt-to-equity ratio of 0.89 and a current ratio of 0.86, indicating that the company has more short-term liabilities than current assets, which could pose liquidity risks if cash flow tightens.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$271.74 billion
P/E Ratio
22.16
Consensus Rating
Hold
Consensus Price Target
$145.60 (-0.9% Downside)
Volume
1.65 million shares
Average Volume
1.83 million shares
Today's Range
$144.17
▼
$147.16
50-Day Range
$137.22
▼
$163.27
52-Week Range
$121.57
▼
$170.46
Dividend Yield
2.14%
Thermo Fisher Scientific stock logo

7. Thermo Fisher Scientific NYSE:TMO

$674.18 +11.14 (+1.68%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$683.11 +8.93 (+1.32%)
As of 05:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • Thermo Fisher Scientific Inc. recently reported strong third-quarter results, beating analyst expectations with earnings per share of $6.03 compared to the consensus estimate of $5.71, while revenue of $11.99 billion also exceeded forecasts, demonstrating robust organic growth driven by a rebound in biotech and pharmaceutical activity.
  • The company has received a "Moderate Buy" consensus rating from twenty-five analysts, with eighteen issuing buy recommendations and two strong buy recommendations, reflecting broad institutional confidence in the firm's long-term positioning in life sciences tools and services.
  • Thermo Fisher Scientific Inc. is expanding its role across the drug lifecycle, including a Phase 2 multiple sclerosis program for Quantum BioPharma and new solutions unveiled at CPHI Milan 2026, which strengthens its long-term strategic positioning in clinical trials and drug manufacturing.

Cons of Thermo Fisher Scientific

  • Several major financial institutions, including Wells Fargo, Citigroup, and BMO Capital Markets, recently downgraded Thermo Fisher Scientific Inc. to underweight or underperform ratings in September 2026, suggesting concerns about the stock's valuation relative to its growth prospects.
  • Insider selling has been significant, with corporate insiders selling 73,768 shares valued at approximately $44.1 million in the last three months, including sales by CEO Marc N. Casper and VP Lisa P. Britt, which may indicate a lack of confidence from company leadership.
  • Thermo Fisher Scientific Inc. is trading at a price-to-earnings ratio of 36.27, which is higher than the market average, and some analysts suggest the stock is trading near fair value, making additional gains dependent on continued earnings beats or stronger guidance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$245.16 billion
P/E Ratio
27.82
Consensus Rating
Moderate Buy
Consensus Price Target
$642.33 (-4.7% Downside)
Volume
2.49 million shares
Average Volume
2.36 million shares
Today's Range
$659.00
▼
$681.50
50-Day Range
$579.85
▼
$681.04
52-Week Range
$435.27
▼
$694.33
Dividend Yield
0.28%
Astrazeneca stock logo

8. Astrazeneca NYSE:AZN

$162.21 +6.39 (+4.10%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$165.16 +2.95 (+1.82%)
As of 05:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Market Capitalization
$241.66 billion
P/E Ratio
24.25
Consensus Rating
Moderate Buy
Consensus Price Target
$206.67 (+27.4% Upside)
Volume
3.33 million shares
Average Volume
2.78 million shares
Today's Range
$158.31
▼
$162.71
50-Day Range
$155.93
▼
$169.50
52-Week Range
$153.41
▼
$212.71
Dividend Yield
2.79%
Amgen stock logo

9. Amgen NASDAQ:AMGN

$426.11 +13.27 (+3.21%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$432.62 +6.51 (+1.53%)
As of 05:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • Amgen Inc. recently reported positive Phase 3 trial results for Tezspire in the treatment of eosinophilic esophagitis, a chronic inflammatory condition with limited approved options. In this study, nearly 70% of patients receiving the higher dose achieved remission at week 24, which could significantly expand the drug's addressable market and provide a new growth driver for the company's pipeline.
  • The stock is currently trading at $426.11, which is well above its 52-week low of $288.00 and approaching its 52-week high of $447.03. This price action reflects strong recent momentum, as the company has consistently beaten earnings estimates, such as the most recent quarter where it reported $6.29 in earnings per share against a consensus estimate of $5.62.
  • Amgen Inc. offers a dividend yield of 2.41%, with a recent quarterly payment of $2.52 per share. This provides a steady income stream for investors, supported by a payout ratio of 62.65%, which indicates the company is distributing a significant portion of its earnings to shareholders while maintaining a current ratio of 1.37 to manage its short-term liabilities.

Cons of Amgen

  • Insider sentiment appears cautious, as corporate insiders have reported seven open-market sales and no purchases during the past six months. For instance, SVP Rachna Khosla sold 2,000 shares in August 2026, and SVP Nancy Grygiel sold 2,970 shares in the same month, which may signal that company executives are taking advantage of the recent stock price appreciation to reduce their personal exposure.
  • Analyst consensus remains mixed, with a current rating of "Hold" and an average price target of $387.93, which is below the current stock price of $426.11. This suggests that many analysts believe the stock may be overvalued relative to its expected future earnings, as the current P/E ratio of 26.48 is higher than the consensus estimate for future growth.
  • The company carries a high debt-to-equity ratio of 4.44, indicating that Amgen Inc. relies heavily on debt financing relative to its shareholder equity. While the company has a quick ratio of 1.13, which shows it can cover short-term obligations, the high leverage could limit financial flexibility if interest rates remain elevated or if revenue growth slows.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$223.19 billion
P/E Ratio
26.48
Consensus Rating
Hold
Consensus Price Target
$387.93 (-9.0% Downside)
Volume
3.08 million shares
Average Volume
3.02 million shares
Today's Range
$415.20
▼
$428.05
50-Day Range
$375.65
▼
$444.12
52-Week Range
$288.00
▼
$447.03
Dividend Yield
2.44%
Gilead Sciences stock logo

10. Gilead Sciences NASDAQ:GILD

$153.54 +5.62 (+3.80%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$155.65 +2.11 (+1.37%)
As of 05:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • The stock is currently trading at $147.10, which is below the consensus price target of $159.26, suggesting potential upside for investors. This valuation gap is supported by a "Moderate Buy" consensus rating from 23 analysts who have issued Buy ratings, indicating strong institutional confidence in the company's future performance relative to its current market price.
  • Gilead Sciences, Inc. demonstrated strong revenue growth in its most recent quarter, reporting $7.80 billion in revenue, which exceeded analyst estimates of $7.40 billion and represented a 10.6% year-over-year increase. This outperformance highlights the company's ability to drive top-line growth, a key metric for investors seeking companies with expanding market share and robust commercial execution.
  • The company has secured a five-year DevOps agreement with Cognizant, a partnership that combines life-sciences expertise with technology services. This strategic move is expected to improve operational efficiency and technology infrastructure, potentially reducing long-term costs and enhancing the scalability of Gilead Sciences, Inc.'s digital capabilities.

Cons of Gilead Sciences

  • The company reported a negative earnings per share (EPS) of ($6.75) in its most recent quarter, resulting in a negative P/E ratio of -55.09. A negative P/E ratio indicates that the company is currently unprofitable on a trailing basis, which can be a concern for value-oriented investors who prioritize consistent earnings generation and positive cash flow from operations.
  • Insider selling has been significant, with CEO Daniel O'Day selling 15,000 shares on October 1, 2026, and other insiders like Johanna Mercier and Andrew Dickinson also selling shares in recent months. While these sales were executed under pre-arranged Rule 10b5-1 trading plans, the consistent pattern of insider disposals can be interpreted as a lack of confidence in the stock's near-term appreciation or a desire to diversify personal holdings.
  • Royal Bank of Canada recently lowered its price objective for Gilead Sciences, Inc. from $123.00 to $126.00, maintaining a "sector perform" rating. This target price implies a potential downside of 13.50% from the current stock price of $147.10, suggesting that some analysts believe the stock is overvalued relative to its fundamental performance and sector peers.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$183.41 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$159.33 (+3.8% Upside)
Volume
5.76 million shares
Average Volume
5.93 million shares
Today's Range
$147.48
▼
$153.76
50-Day Range
$130.86
▼
$153.54
52-Week Range
$114.02
▼
$157.29
Dividend Yield
2.22%
Abbott Laboratories stock logo

11. Abbott Laboratories NYSE:ABT

$103.04 +0.43 (+0.42%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$103.35 +0.31 (+0.30%)
As of 05:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • Abbott Laboratories recently received FDA approval for updates to its CardioMEMS heart-failure system, which now integrates with the CardioGuide HF App to provide smartphone-based pulmonary-pressure readings and clinician-guided treatment adjustments, strengthening its connected cardiac-care offering and supporting future adoption.
  • Wall Street analysts maintain a consensus rating of Moderate Buy with an average price target of $119.50, which implies significant upside potential from the current stock price of $98.46, reflecting a view that the stock is undervalued relative to its fundamentals.
  • The company offers a dividend yield of 2.57% and has a record of 411 consecutive quarterly dividend payments, making it an attractive option for income-focused investors seeking consistent payouts despite the stock's recent performance.

Cons of Abbott Laboratories

  • Despite bullish analyst commentary, Abbott Laboratories has remained under pressure after a difficult 2026 performance, with the stock trading at $98.46, well below its 52-week high of $135.13, indicating significant downside risk and investor skepticism.
  • The company has a relatively elevated earnings multiple with a P/E ratio of 31.86, which may limit investor enthusiasm given that Abbott is not showing rapid growth trends, making the valuation less attractive compared to higher-growth peers.
  • Gradient Investments LLC lowered its position in Abbott Laboratories shares by 24.2% during the third quarter, selling 57,265 shares, which suggests that some institutional investors are reducing their exposure to the stock.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$177.55 billion
P/E Ratio
33.35
Consensus Rating
Moderate Buy
Consensus Price Target
$118.88 (+15.4% Upside)
Volume
7.27 million shares
Average Volume
9.51 million shares
Today's Range
$101.69
▼
$104.06
50-Day Range
$96.62
▼
$116.70
52-Week Range
$81.97
▼
$132.02
Dividend Yield
2.46%
Novo Nordisk A/S stock logo

12. Novo Nordisk A/S NYSE:NVO

$38.14 +0.08 (+0.22%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$38.60 +0.46 (+1.20%)
As of 05:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • Novo Nordisk is currently trading at $38.19, which is significantly below its 52-week high of $64.16, offering a potential entry point for value-oriented investors who believe the market has overreacted to recent challenges.
  • The company has a low price-to-earnings ratio of 9.34, indicating that the stock is priced at a discount relative to its earnings power, which may be attractive to fundamental analysts looking for undervalued pharmaceutical assets.
  • Novo Nordisk is continuing a share-repurchase program that forms part of a planned DKK 15 billion, 12-month buyback, which can provide support for earnings per share and signal management confidence in the valuation.

Cons of Novo Nordisk A/S

  • Competition in obesity treatments is intensifying, with reports indicating that Novo Nordisk is losing market share as investors question whether its pipeline beyond GLP-1 therapies is broad enough to sustain growth against rivals like Eli Lilly.
  • The FDA extended its review of denecimig, Novo Nordisk’s hemophilia A treatment, due to remediation work at a manufacturing facility, which postpones a potential product launch and highlights ongoing manufacturing risks.
  • Wall Street analysts have a consensus rating of "Hold" with a target price of $64.94, suggesting limited near-term upside potential, while several firms, including Wall Street Zen and CFRA, have recently downgraded or turned bearish on the stock.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$169.94 billion
P/E Ratio
9.33
Consensus Rating
Hold
Consensus Price Target
$59.44 (+55.8% Upside)
Volume
9.31 million shares
Average Volume
15.41 million shares
Today's Range
$37.90
▼
$38.42
50-Day Range
$37.31
▼
$48.65
52-Week Range
$35.12
▼
$64.16
Dividend Yield
2.14%
Pfizer stock logo

13. Pfizer NYSE:PFE

$29.22 +0.85 (+2.99%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$29.49 +0.27 (+0.94%)
As of 05:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • Pfizer Inc. recently received FDA approval for its TUKYSA regimen in combination with trastuzumab and pertuzumab as a front-line maintenance treatment for adults with HER2-positive metastatic breast cancer, expanding the drug's addressable market and supporting oncology revenue growth.
  • The company reported positive Phase 3 results for LITFULO in nonsegmental vitiligo, demonstrating meaningful facial and total-body repigmentation with favorable tolerability, which could broaden the drug's commercial opportunity and strengthen the immunology pipeline.
  • Pfizer Inc. declared a quarterly dividend of $0.43 per share, representing an annualized yield of approximately 6.25%, which is attractive to income-focused investors seeking returns above the 10-year Treasury note.

Cons of Pfizer

  • Analysts have flagged risks regarding the sustainability of Pfizer Inc.'s high dividend yield, noting a dividend payout ratio of 226.32% which exceeds earnings, raising concerns about long-term dividend reliability.
  • The company plans to cut approximately 330 jobs at its Sicily, Italy facility, highlighting ongoing cost pressure and restructuring needs that may signal continued operational challenges.
  • Pfizer Inc. has a debt-to-equity ratio of 0.71 and a quick ratio of 0.96, indicating elevated debt levels and potential liquidity constraints that could impact financial flexibility.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$161.70 billion
P/E Ratio
38.44
Consensus Rating
Hold
Consensus Price Target
$28.72 (-1.7% Downside)
Volume
39.31 million shares
Average Volume
32.06 million shares
Today's Range
$28.55
▼
$29.49
50-Day Range
$26.18
▼
$29.22
52-Week Range
$23.62
▼
$29.49
Dividend Yield
6.06%
Danaher stock logo

14. Danaher NYSE:DHR

$224.65 +1.81 (+0.81%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$228.24 +3.58 (+1.59%)
As of 05:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • Danaher Co. announced plans to launch an AI-powered autonomous research lab in 2027, a development that has already driven a 2% stock increase and attracted significant analyst attention, including a price target hike from Barclays to $255.00, suggesting strong future growth potential in the life sciences sector.
  • The company recently reported strong third-quarter earnings, beating analyst expectations with $1.94 in earnings per share compared to the consensus estimate of $1.85, while also exceeding revenue forecasts with $6.26 billion in sales, demonstrating robust operational performance and demand for its diagnostic and biotechnology products.
  • Institutional investor confidence is high, with 79.05% of the stock owned by institutions, and recent filings show significant new positions being acquired by firms like Farther Finance Advisors LLC, which increased its holdings by 760.6% in the third quarter, indicating strong professional market support for the stock.

Cons of Danaher

  • The stock has experienced significant volatility recently, including a gap down of over 32 points on July 21, 2026, and a decline to 52-week lows in May 2026, indicating potential market uncertainty or concerns about the company's short-term performance and stability.
  • Danaher Co. carries a relatively high price-to-earnings ratio of 38.60, which may be considered expensive for some investors, especially if the company's earnings growth does not accelerate to justify the premium valuation in the current economic environment.
  • The company has a debt-to-equity ratio of 0.48, which, while manageable, indicates a moderate level of leverage that could become a concern if interest rates rise or if the company faces unexpected operational challenges, potentially impacting its financial flexibility.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$156.65 billion
P/E Ratio
39.90
Consensus Rating
Moderate Buy
Consensus Price Target
$235.41 (+4.8% Upside)
Volume
3.60 million shares
Average Volume
4.72 million shares
Today's Range
$222.74
▼
$227.86
50-Day Range
$199.62
▼
$227.51
52-Week Range
$160.93
▼
$242.80
Dividend Yield
0.72%
Intuitive Surgical stock logo

15. Intuitive Surgical NASDAQ:ISRG

$420.24 -1.82 (-0.43%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$422.53 +2.29 (+0.54%)
As of 05:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • Intuitive Surgical, Inc. recently demonstrated strong financial performance by beating consensus estimates in its most recent quarterly report, posting earnings per share of $2.80 against an expected $2.48 and generating revenue of $2.89 billion, which represented an 18.4% year-over-year increase. This consistent ability to exceed analyst expectations for both earnings and revenue suggests robust operational execution and demand for the company's robotic-assisted systems, providing a fundamental basis for potential stock appreciation.
  • The stock is currently trading at $415.41, which is significantly below the consensus price target of $508.68 set by analysts as of September 2026. This valuation gap implies that the market may be undervaluing the company relative to its projected growth, offering investors a potential entry point with substantial upside potential if the stock reverts to the mean of analyst expectations.
  • Wall Street sentiment remains strongly positive, with a consensus rating of "Moderate Buy" and recent upgrades from major firms such as Barclays, which raised its rating to "Strong Buy," and Piper Sandler, which issued a "Buy" recommendation. These recent actions indicate that institutional investors and analysts have high confidence in the company's long-term trajectory and market position, which can drive sustained buying interest.

Cons of Intuitive Surgical

  • Intuitive Surgical, Inc. faces intensifying competition, particularly from major healthcare conglomerates like Johnson & Johnson, which are actively entering the robotic surgery space. This increased rivalry could erode the company's market share and pricing power, as competitors offer alternative solutions that may be more cost-effective or integrated into existing hospital systems, posing a significant threat to the company's dominant position.
  • The stock carries a premium valuation with a P/E ratio of 47.58, which is high relative to many other healthcare companies. This elevated multiple leaves little room for error, meaning that any slight miss in earnings or guidance could trigger a sharp decline in the stock price, as investors may quickly reassess the company's growth prospects and demand a lower valuation.
  • Insider selling activity has been notable, with executives and directors such as Gary Guthart and Mark Brosius selling significant numbers of shares in recent months. While these sales may be part of pre-arranged trading plans, a consistent pattern of insider selling can be interpreted as a signal that company insiders believe the stock is overvalued or that they are diversifying their personal wealth, which may dampen investor sentiment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$149.10 billion
P/E Ratio
48.14
Consensus Rating
Moderate Buy
Consensus Price Target
$498.83 (+18.7% Upside)
Volume
1.91 million shares
Average Volume
2.12 million shares
Today's Range
$414.65
▼
$425.50
50-Day Range
$350.16
▼
$427.64
52-Week Range
$328.57
▼
$603.88
Dividend Yield
N/A
Vertex Pharmaceuticals stock logo

16. Vertex Pharmaceuticals NASDAQ:VRTX

$498.50 +13.28 (+2.74%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$496.39 -2.11 (-0.42%)
As of 04:57 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • Vertex Pharmaceuticals Incorporated recently crossed above its 200-day moving average of $477.12, a technical indicator that often signals a shift from a long-term downtrend to a potential uptrend, suggesting that recent buying pressure is strong enough to overcome previous selling pressure and that the stock is currently trading at $503.25.
  • The company demonstrated strong fundamental performance in its most recent earnings report on August 3rd, 2026, where it reported revenue of $3.33 billion, which exceeded analyst estimates of $3.23 billion, and achieved a year-over-year revenue growth of 12.5%, indicating robust demand for its therapies despite a slight miss in earnings per share.
  • Wall Street analysts maintain a positive outlook on the stock, with a consensus rating of "Moderate Buy" and an average price target of $575.13, which represents significant upside potential from the current price, supported by recent price target increases from firms like UBS Group and Cantor Fitzgerald.

Cons of Vertex Pharmaceuticals

  • There is a notable pattern of insider selling, with multiple executives including EVP Ourania Tatsis and EVP Duncan McKechnie selling shares in July 2026, and CMO Carmen Bozic selling significant amounts of stock in May and June 2026, which can sometimes signal that insiders believe the stock is overvalued or that they are diversifying their personal wealth.
  • The company's earnings per share of $4.73 in the most recent quarter slightly missed the consensus estimate of $4.74, and while revenue beat expectations, the margin between actual and expected earnings suggests that cost pressures or operational challenges may be impacting profitability more than anticipated.
  • Short interest in the stock has been increasing, with shares shorted rising to 4,716,867 as of September 15, 2026, up from 4,659,749 in the previous month, indicating that a growing number of traders are betting against the stock's price appreciation, which could create downward pressure on the share price.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$123.15 billion
P/E Ratio
28.51
Consensus Rating
Moderate Buy
Consensus Price Target
$579.81 (+16.3% Upside)
Volume
2.09 million shares
Average Volume
1.08 million shares
Today's Range
$487.54
▼
$502.94
50-Day Range
$484.03
▼
$557.96
52-Week Range
$403.16
▼
$560.25
Dividend Yield
N/A
Medtronic stock logo

17. Medtronic NYSE:MDT

$94.14 +1.13 (+1.21%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$94.86 +0.73 (+0.77%)
As of 05:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • Medtronic plc shares are currently trading at $91.61, which is significantly below the consensus price target of $102.92 set by twenty-eight brokerages, suggesting a potential upside of over 12% for investors who believe the market has undervalued the company's recent performance and strategic initiatives.
  • The company recently reported strong financial results for the quarter ending September 1, 2026, with actual earnings per share of $1.45 beating the consensus estimate of $1.39, and revenue of $9.756 billion exceeding the expected $9.546 billion, demonstrating robust operational execution and demand for its medical device portfolio.
  • Medtronic plc has successfully oversubscribed its exchange offer for MiniMed Group shares, a move that supports the company's strategy of separating its diabetes business to focus on its core medical-device operations, which may streamline management and improve long-term shareholder value.

Cons of Medtronic

  • Short interest in Medtronic plc has surged significantly, with shares shorted increasing by 132.0% to 39,974,230 shares as of September 30, 2026, indicating that a substantial portion of the market is betting against the stock's future performance.
  • The stock has underperformed the broader market over the past year, declining by over 7% while the general market gained 17%, which may signal persistent structural challenges or a lack of investor confidence in the company's ability to drive growth in its current market environment.
  • Medtronic plc is facing significant capital expenditure pressures due to heavy spending on new technology areas such as robotics and cardiac ablation, which could impact near-term profitability and cash flow generation as the company invests in its future growth platforms.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$118.97 billion
P/E Ratio
23.19
Consensus Rating
Moderate Buy
Consensus Price Target
$102.88 (+9.3% Upside)
Volume
49.86 million shares
Average Volume
29.19 million shares
Today's Range
$92.16
▼
$94.72
50-Day Range
$85.51
▼
$94.14
52-Week Range
$73.31
▼
$106.33
Dividend Yield
3.10%
Bristol Myers Squibb stock logo

18. Bristol Myers Squibb NYSE:BMY

$59.34 +2.67 (+4.72%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$60.34 +0.99 (+1.67%)
As of 05:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol Myers Squibb

Pros of Bristol Myers Squibb

  • Bristol-Myers Squibb recently announced positive Phase 3 data for Zenbexus (iberdomide), which demonstrated superior progression-free survival compared to standard of care in relapsed and refractory multiple myeloma, strengthening the company's pipeline and providing a potential future growth driver in a competitive market.
  • The company reported strong third-quarter earnings, beating consensus estimates with $2.04 in earnings per share against an expected $1.60, and revenue of $12.97 billion, which exceeded the consensus estimate of $11.74 billion, indicating robust operational performance and top-line growth of 5.7% year-over-year.
  • Investors can benefit from a high dividend yield of 4.23%, with the company recently declaring a quarterly dividend of $0.63 per share, offering a substantial income stream that is supported by a payout ratio of 55.51%, which leaves room for financial flexibility.

Cons of Bristol Myers Squibb

  • Analysts continue to highlight patent-cliff concerns, noting that patent expirations and declining sales of legacy drugs could pressure revenue, making the successful launch of new products and pipeline development critical for maintaining financial health.
  • Cantor Fitzgerald recently lowered its price target for Bristol-Myers Squibb from $59.00 to $53.00 and maintained a neutral rating, signaling limited near-term upside in its view, while Morgan Stanley issued a Sell rating, indicating significant bearish sentiment from some major financial institutions.
  • Adoption of Sotyktu for psoriatic arthritis is developing unevenly, as rheumatologists cite limited experience, access hurdles, and questions about joint efficacy, which are restraining the launch momentum of this newer therapy despite its differentiation in the market.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$115.76 billion
P/E Ratio
13.07
Consensus Rating
Hold
Consensus Price Target
$64.88 (+9.3% Upside)
Volume
14.04 million shares
Average Volume
14.53 million shares
Today's Range
$56.58
▼
$59.39
50-Day Range
$56.73
▼
$68.06
52-Week Range
$42.52
▼
$68.64
Dividend Yield
4.45%
McKesson stock logo

19. McKesson NYSE:MCK

$977.31 +15.43 (+1.60%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$988.00 +10.69 (+1.09%)
As of 04:18 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • McKesson Co. is expanding its healthcare platform through a $5.8 billion acquisition of Option Care Health, a move that provides exposure to the growing home and outpatient infusion market as complex treatments shift away from hospitals.
  • The company demonstrated strong financial performance in its most recent quarter, reporting earnings per share of $9.93, which exceeded analyst estimates of $9.56, while revenue grew 7.7% year-over-year to $105.38 billion.
  • McKesson Co. recently increased its quarterly dividend to $0.94, representing a 14.6% increase from the previous $0.82 payment, which supports income-focused investors with a current yield of 0.40%.

Cons of McKesson

  • The planned $1.4 billion investment in the Option Care Health acquisition represents a substantial capital commitment that could pressure near-term returns if expected synergies or growth in home infusion take longer to materialize.
  • Corporate insiders have been selling shares recently, including CEO Brian Tyler who sold 8,463 shares in July 2026 and CAO Napoleon B. Rutledge Jr. who sold 111 shares in September 2026, which may signal a lack of confidence in near-term upside.
  • McKesson Co. is trading near its 52-week high of $999.00, with the current price of $954.65 leaving limited room for further appreciation before potential valuation concerns arise.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$112.15 billion
P/E Ratio
26.15
Consensus Rating
Moderate Buy
Consensus Price Target
$983.29 (+0.6% Upside)
Volume
767,923 shares
Average Volume
812,714 shares
Today's Range
$965.05
▼
$979.82
50-Day Range
$841.21
▼
$977.31
52-Week Range
$723.68
▼
$999.00
Dividend Yield
0.39%
CVS Health stock logo

20. CVS Health NYSE:CVS

$90.42 +2.87 (+3.27%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$91.38 +0.96 (+1.07%)
As of 05:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • CVS Health Co. recently reported strong third-quarter earnings, beating analyst expectations with an actual earnings per share of $2.58 compared to the consensus estimate of $1.87, demonstrating the company's ability to outperform market forecasts and drive shareholder value through operational efficiency.
  • The stock is currently trading at $87.93, which is significantly below the consensus price target of $107.24 set by Wall Street analysts, suggesting a potential upside of approximately 22% for investors who believe the market is currently undervaluing the company's turnaround efforts.
  • CVS Health Co. has raised its full-year 2026 earnings per share guidance to a range of $7.90 to $8.10, which is well above the previous consensus estimate of $7.44, indicating management's confidence in sustained revenue growth and cost management throughout the remainder of the fiscal year.

Cons of CVS Health

  • CVS Health Co. faces significant regulatory and reputational risk following the initiation of an investigation by Kahn Swick & Foti, LLC into the company's officers and directors, which could lead to legal costs, management distraction, and potential financial liabilities that are not yet reflected in the current stock price.
  • The company's Aetna unit received weaker-than-expected Medicare Advantage star ratings for 2027, with TD Cowen estimating this could result in a $0.41 hit to earnings per share, highlighting ongoing challenges in maintaining high-quality clinical performance and member satisfaction in a competitive insurance market.
  • Despite recent earnings beats, the stock has experienced a sharp retreat from its summer highs, with a gap down of 10.7% observed in August 2026, suggesting that investors may be pricing in structural headwinds such as increasing medical costs and reimbursement pressures that could limit future profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$111.97 billion
P/E Ratio
23.92
Consensus Rating
Moderate Buy
Consensus Price Target
$107.80 (+19.2% Upside)
Volume
9.33 million shares
Average Volume
9.97 million shares
Today's Range
$88.10
▼
$90.78
50-Day Range
$84.96
▼
$97.36
52-Week Range
$69.51
▼
$110.68
Dividend Yield
3.04%
Stryker stock logo

21. Stryker NYSE:SYK

$281.78 -0.77 (-0.27%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$284.94 +3.16 (+1.12%)
As of 04:52 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • Stryker Co. recently announced a planned leadership succession where Spencer Stiles, the current President and Chief Operating Officer, will succeed Kevin Lobo as Chief Executive Officer effective January 1, 2027, while Lobo transitions to the role of Executive Chair. This internal transition is viewed by analysts as a low-risk move that provides continuity, as Stiles is an established internal leader familiar with the company's operations and strategy, which supports the view that the transition should not materially disrupt execution.
  • The stock is currently trading at $276.56, which is near its 52-week low of $267.00, presenting a potential value opportunity as the price has declined significantly from its 52-week high of $392.55. This drop has brought the valuation to a level that some analysts, such as Barclays, have recently upgraded to a "strong-buy" rating, suggesting the stock may be undervalued relative to its long-term growth potential and medical device market position.
  • Stryker Co. demonstrated strong financial performance in its most recent earnings report on July 30, 2026, where it reported earnings per share of $3.69, topping the consensus estimate of $3.49 by $0.20. The company also achieved a net margin of 14.43% and a return on equity of 23.63%, with quarterly revenue of $6.59 billion, which was up 9.4% on a year-over-year basis, indicating robust operational efficiency and growth.

Cons of Stryker

  • Pomerantz LLP has announced an investigation into potential claims on behalf of Stryker Co. investors, which adds sentiment and headline risk to the stock. Although the announcement does not establish wrongdoing, such legal investigations can lead to increased volatility and potential financial liabilities, which may weigh on investor confidence and the company's stock price in the near term.
  • Insider selling activity has been significant, with insiders selling 351,267 shares of company stock valued at $118,197,701 over the last 90 days. Notable sales include Director Ronda E Stryker selling 300,000 shares at an average price of $335.90 and 50,000 shares at $340.10 in August 2026, which may signal a lack of confidence from those with the most insight into the company's internal operations and future prospects.
  • The stock has experienced a substantial decline, dropping 26% from its recent highs, and is currently trading below its 50-day simple moving average of $306.83 and 200-day simple moving average of $315.02. This technical weakness, combined with the stock's position near its 52-week low, suggests that downward momentum may persist, and investors may face further capital losses if the trend continues.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$108.38 billion
P/E Ratio
29.20
Consensus Rating
Moderate Buy
Consensus Price Target
$369.00 (+31.0% Upside)
Volume
2.22 million shares
Average Volume
2.61 million shares
Today's Range
$278.58
▼
$285.66
50-Day Range
$269.98
▼
$347.34
52-Week Range
$267.00
▼
$392.55
Dividend Yield
1.25%
HCA Healthcare stock logo

22. HCA Healthcare NYSE:HCA

$470.25 +9.50 (+2.06%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$473.78 +3.54 (+0.75%)
As of 04:58 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • The stock is currently trading at $458.69, which is below the average analyst price target of $466.35, suggesting potential for upside as the consensus rating remains a Moderate Buy.
  • HCA Healthcare, Inc. recently reported Q2 2026 earnings of $7.59 per share, beating the consensus estimate of $7.56, while revenue of $20.23 billion exceeded expectations and grew 8.7% year-over-year.
  • The company maintains a consistent dividend policy, having recently paid a quarterly dividend of $0.78 per share, which annualizes to $3.12 and provides a yield of approximately 0.7% for income-focused investors.

Cons of HCA Healthcare

  • The stock has experienced significant volatility, trading down from a 52-week high of $556.52 to the current price of $458.69, reflecting a substantial drawdown that may signal underlying market concerns.
  • Legal risks are present, as Pomerantz LLP is currently investigating claims on behalf of investors of HCA Healthcare, Inc., which could lead to potential liabilities or reputational damage.
  • Operational challenges are emerging, with reports indicating that HCA nurses have raised questions over an AI-enabled scheduling tool, suggesting potential friction in workforce management and technology adoption.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$99.75 billion
P/E Ratio
15.51
Consensus Rating
Moderate Buy
Consensus Price Target
$467.61 (-0.6% Downside)
Volume
1.08 million shares
Average Volume
1.35 million shares
Today's Range
$457.80
▼
$472.39
50-Day Range
$401.80
▼
$470.25
52-Week Range
$353.99
▼
$556.52
Dividend Yield
0.68%
Sanofi stock logo

23. Sanofi NASDAQ:SNY

$39.77 +0.65 (+1.66%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$40.49 +0.72 (+1.81%)
As of 05:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • Sanofi recently expanded its global alliance with Regeneron in a deal valued at up to $8 billion, which includes a $1 billion upfront payment and adds four next-generation, long-acting antibodies to the pipeline that has already produced the blockbuster therapy Dupixent, providing a significant catalyst for future growth in type 2 inflammatory diseases.
  • The company is currently trading at $39.74, which is near its 52-week low of $39.18, offering a potential entry point for investors given that the consensus price target from analysts is $49.50, suggesting substantial upside potential relative to the current market price.
  • Sanofi offers a high dividend yield of 4.39%, which is attractive for income-focused investors, and the company recently raised its dividend by over 10%, demonstrating a commitment to returning capital to shareholders while maintaining a stable payout.

Cons of Sanofi

  • The consensus rating from analysts is currently "Hold," with a recent downgrade by Wall Street Zen from "Buy" to "Hold" and a downgrade by Weiss Ratings to "Sell," reflecting a lack of strong bullish conviction among research firms despite the recent partnership news.
  • Short interest in Sanofi has been increasing, with shares shorted rising to over 10.6 million shares as of the most recent reporting period, indicating that a significant portion of the market is betting against the stock's future performance.
  • The company's price-to-earnings ratio of 20.81 is relatively high compared to some peers, and the PEG ratio of 1.21 suggests that the stock may be overvalued relative to its expected earnings growth, limiting the margin of safety for new investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$94.84 billion
P/E Ratio
20.82
Consensus Rating
Hold
Consensus Price Target
$49.50 (+24.5% Upside)
Volume
5.34 million shares
Average Volume
3.19 million shares
Today's Range
$39.33
▼
$40.00
50-Day Range
$39.12
▼
$46.02
52-Week Range
$39.07
▼
$52.68
Dividend Yield
4.51%
GSK stock logo

24. GSK NYSE:GSK

$47.92 +1.65 (+3.57%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$48.20 +0.28 (+0.59%)
As of 05:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • GSK plc is currently trading at $46.52, which is significantly below the average 12-month analyst price target of $56.50, suggesting substantial upside potential for investors who believe the market is undervaluing the company's recent pipeline additions and strategic initiatives.
  • The company has successfully expanded its oncology pipeline through recent high-profile deals, including a $10.6 billion acquisition of Nuvalent and a licensing agreement with HUTCHMED for HMPL-A830, which aims to diversify growth beyond its existing core products and address the upcoming patent cliff in its HIV franchise.
  • GSK plc offers an attractive dividend yield of 3.81%, supported by a recent increase in its quarterly dividend to $0.4515, providing a steady income stream for investors while the company maintains a payout ratio of 55.63% that leaves room for further growth investments.

Cons of GSK

  • The consensus rating from eleven brokerages covering GSK plc is "Hold," with two analysts issuing sell ratings, indicating that a significant portion of the financial community is cautious about the stock's near-term performance and potential risks.
  • GSK faces a significant patent cliff in its HIV franchise, which could lead to a substantial loss of revenue unless the company successfully executes its strategy of reinvesting cost savings into R&D and M&A to offset the impact of expiring patents.
  • Recent labor advocacy efforts to preserve jobs at GSK's Dresden vaccine plant in Germany highlight potential workforce and restructuring concerns, which could create execution costs or reputational pressure for the company.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$93.59 billion
P/E Ratio
14.98
Consensus Rating
Hold
Consensus Price Target
$55.33 (+15.5% Upside)
Volume
7.09 million shares
Average Volume
5.06 million shares
Today's Range
$46.55
▼
$47.98
50-Day Range
$46.24
▼
$53.08
52-Week Range
$42.85
▼
$61.69
Dividend Yield
3.77%
Elevance Health stock logo

25. Elevance Health NYSE:ELV

$427.64 +2.37 (+0.56%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$424.55 -3.09 (-0.72%)
As of 04:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$92.23 billion
P/E Ratio
19.01
Consensus Rating
Moderate Buy
Consensus Price Target
$441.71 (+3.3% Upside)
Volume
2.12 million shares
Average Volume
1.21 million shares
Today's Range
$421.78
▼
$434.00
50-Day Range
$381.68
▼
$427.64
52-Week Range
$274.84
▼
$436.24
Dividend Yield
1.63%
Moderna stock logo

26. Moderna NASDAQ:MRNA

$226.30 +10.05 (+4.65%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$223.42 -2.88 (-1.27%)
As of 05:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. More about Moderna

Pros of Moderna

  • Moderna, Inc. is scheduled to join the Nasdaq-100 index before the October 9 open, replacing Warner Bros. Discovery, which is expected to increase demand from index-tracking funds and boost the company's visibility in the market.
  • The company recently announced an expanded multi-year collaboration with Tempus and Merck to support the potential commercialization of intismeran autogene (V940/mRNA-4157), a personalized neoantigen cancer therapy being tested in combination with Keytruda for melanoma and other cancers, reinforcing the commercial potential of its cancer-vaccine platform.
  • Investor interest remains elevated ahead of the anticipated full Phase 3 melanoma-vaccine data readout, as the mRNA-4157 program developed with Merck is viewed as a key potential growth driver for the company beyond its COVID-19 vaccines.

Cons of Moderna

  • Morgan Stanley recently raised its price target to $95 but retained an "equal weight" rating, which represents a potential downside of over 50% from the current stock price of $196.48, suggesting that the recent surge may have outpaced the company's fundamentals.
  • The consensus rating for Moderna, Inc. remains "Hold" with an average price target of $78.17, which is significantly lower than the current market price, indicating that many sell-side analysts believe the stock is overvalued relative to its projected earnings.
  • Insiders have sold 118,882 shares of company stock worth approximately $16.86 million over the last 90 days, including significant sales by President Stephen Hoge and other executives, which may signal a lack of confidence in the stock's future performance from those closest to the company.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$86.33 billion
P/E Ratio
N/A
Consensus Rating
Hold
Consensus Price Target
$100.60 (-55.5% Downside)
Volume
16.56 million shares
Average Volume
18.00 million shares
Today's Range
$211.24
▼
$227.09
50-Day Range
$53.86
▼
$226.30
52-Week Range
$22.28
▼
$227.46
Dividend Yield
N/A
Regeneron Pharmaceuticals stock logo

27. Regeneron Pharmaceuticals NASDAQ:REGN

$778.36 +25.24 (+3.35%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$787.25 +8.89 (+1.14%)
As of 05:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • Regeneron Pharmaceuticals, Inc. recently reported positive 84-week data for its newly approved drug Pasatru, which demonstrated zero new heterotopic ossification lesions in patients with fibrodysplasia ossificans progressiva, a rare disease, providing strong evidence of long-term efficacy and supporting the commercial viability of this first-in-class treatment.
  • The company significantly outperformed market expectations in its most recent quarterly earnings report, delivering earnings per share of $14.29 against a consensus estimate of $10.16 and generating revenue of $4.29 billion, which exceeded the projected $3.82 billion, indicating robust financial health and strong demand for its therapeutic portfolio.
  • With the current stock price at $778.36, Regeneron Pharmaceuticals, Inc. trades at a price-to-earnings ratio of 19.24, which is notably lower than the median multiple of the S&P 500, suggesting that the stock may be undervalued relative to broader market peers despite its strong growth trajectory and recent earnings beats.

Cons of Regeneron Pharmaceuticals

  • Corporate insiders have engaged in consistent selling activity, with directors and executives such as Kathryn Guarini and Huda Zoghbi selling thousands of shares in recent months, which may signal a lack of confidence in the stock's near-term upside or a desire to diversify personal holdings.
  • The stock is currently trading below its 50-day moving average of $790.91, suggesting that short-term momentum has weakened after a period of volatility, including a significant gap down in May 2026, which could indicate technical resistance or a cooling of investor enthusiasm.
  • Regeneron Pharmaceuticals, Inc. has a relatively low dividend yield of 0.49%, which may be insufficient to attract income-focused investors who prefer higher payout ratios, especially when compared to other mature pharmaceutical companies that offer more substantial cash returns.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$77.54 billion
P/E Ratio
19.24
Consensus Rating
Moderate Buy
Consensus Price Target
$834.24 (+7.2% Upside)
Volume
878,228 shares
Average Volume
770,702 shares
Today's Range
$755.21
▼
$781.84
50-Day Range
$726.47
▼
$852.03
52-Week Range
$564.00
▼
$859.34
Dividend Yield
0.50%
Cigna Group stock logo

28. Cigna Group NYSE:CI

$289.57 +7.04 (+2.49%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$292.00 +2.43 (+0.84%)
As of 04:55 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about Cigna Group

Pros of Cigna Group

  • The Cigna Group recently launched Health Sense, a new platform designed to connect guidance, benefits, and clinical support around each person, which the company projects will reduce inefficient health care spending by 10% by 2030, potentially improving affordability for employers and customers alike.
  • With a current stock price of $279.07, The Cigna Group trades at a P/E ratio of 11.55, which is significantly lower than the broader market average, suggesting the stock may be undervalued relative to its earnings potential and offering a margin of safety for value-oriented investors.
  • The company has demonstrated strong recent financial performance, reporting $7.78 in earnings per share for the most recent quarter, which exceeded analyst consensus estimates of $7.60, and revenue of $71.56 billion, surpassing the expected $70.14 billion, indicating robust operational execution.

Cons of Cigna Group

  • Insider selling activity has been notable recently, with CEO David Cordani selling 201,878 shares in May 2026 and other insiders like Nicole Jones and Everett Neville also reducing their positions, which may signal a lack of confidence in the stock's near-term upside from those closest to the company.
  • Short interest in The Cigna Group has increased, with shares shorted rising to 6,562,998 as of September 2026, representing a 4.59% month-over-month increase, suggesting that a growing number of traders are betting on a decline in the stock price.
  • Some institutional investors have reduced their exposure, such as CX Institutional, which decreased its holdings by 67.3% in the third quarter, and Jefferies Financial Group downgraded the stock from Buy to Hold while cutting its price target, indicating potential concerns about valuation or growth sustainability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$74.66 billion
P/E Ratio
11.98
Consensus Rating
Moderate Buy
Consensus Price Target
$338.24 (+16.8% Upside)
Volume
1.40 million shares
Average Volume
1.64 million shares
Today's Range
$283.56
▼
$290.08
50-Day Range
$265.54
▼
$290.11
52-Week Range
$239.51
▼
$311.34
Dividend Yield
2.20%
Cencora stock logo

29. Cencora NYSE:COR

$335.85 +5.74 (+1.74%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$339.69 +3.84 (+1.14%)
As of 04:56 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • Leerink Partners recently raised its price target on Cencora, Inc. from $380.00 to $388.00, maintaining an "outperform" rating, which suggests significant potential upside relative to the current stock price of $316.68.
  • The company demonstrated strong financial performance in its most recent quarter, reporting earnings per share of $4.48, which beat analyst consensus estimates of $4.35, alongside revenue of $84.75 billion that exceeded expectations of $84.31 billion.
  • Cencora, Inc. has a low beta of 0.58, indicating that the stock is less volatile than the broader market, which may appeal to investors seeking stability in their healthcare portfolio.

Cons of Cencora

  • The company has a high debt-to-equity ratio of 3.53, which indicates a significant level of leverage relative to its equity, potentially increasing financial risk during economic downturns.
  • Insider selling activity has been notable, with EVP Elizabeth Campbell selling 11,300 shares in August 2026 and CEO Robert P. Mauch selling 5,096 shares in January 2026, which may signal reduced internal confidence.
  • Cencora, Inc. has a relatively low net margin of 0.79%, meaning the company retains very little profit from each dollar of revenue, which can limit its ability to invest in growth or weather cost increases.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$62.99 billion
P/E Ratio
24.95
Consensus Rating
Moderate Buy
Consensus Price Target
$365.69 (+8.9% Upside)
Volume
1.19 million shares
Average Volume
1.25 million shares
Today's Range
$330.82
▼
$336.33
50-Day Range
$300.71
▼
$336.98
52-Week Range
$244.82
▼
$377.54
Dividend Yield
0.73%
Boston Scientific stock logo

30. Boston Scientific NYSE:BSX

$43.03 -0.28 (-0.64%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$43.44 +0.40 (+0.93%)
As of 05:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • Boston Scientific Co. is currently trading at $43.78, which is near its 52-week low of $41.38, offering a potential entry point for value-oriented investors. The stock has a price-to-earnings ratio of 17.73, which is relatively low for a medical technology company, suggesting that the market may be undervaluing the company's future earnings potential compared to its historical performance.
  • The company demonstrated strong financial performance in its most recent quarter, reporting earnings per share of $0.86, which beat the consensus estimate of $0.83. Revenue also exceeded expectations at $5.44 billion, up 7.5% year-over-year, indicating robust demand for its medical devices and effective execution of its business strategy.
  • Boston Scientific Co. has a low beta of 0.58, meaning its stock price tends to be less volatile than the overall market. This characteristic can make it a suitable investment for risk-averse investors or those looking to stabilize their portfolio during periods of market uncertainty.

Cons of Boston Scientific

  • The stock has experienced a significant decline, reaching a 52-week low of $41.38, which is a substantial drop from its 52-week high of $105.65. This downward trend may indicate underlying issues with the company's business model or market conditions that could continue to pressure the stock price.
  • Analysts have recently lowered their price targets for Boston Scientific Co., with Leerink Partners cutting its target from $60.00 to $55.00 and Wells Fargo lowering its target from $50.00 to $48.00. These reductions suggest that analysts are becoming more cautious about the company's future growth prospects.
  • The company's guidance for the current fiscal year is below the consensus estimate, with Boston Scientific Co. projecting earnings per share of $3.280 to $3.320, while analysts expect $3.360. This gap may indicate that the company is facing challenges in meeting market expectations, which could lead to further stock price declines.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$62.77 billion
P/E Ratio
17.42
Consensus Rating
Moderate Buy
Consensus Price Target
$68.23 (+58.6% Upside)
Volume
15.09 million shares
Average Volume
19.20 million shares
Today's Range
$42.28
▼
$43.58
50-Day Range
$41.55
▼
$52.02
52-Week Range
$41.38
▼
$105.65
Dividend Yield
N/A
Takeda Pharmaceutical stock logo

31. Takeda Pharmaceutical NYSE:TAK

$19.03 +0.51 (+2.78%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$19.36 +0.33 (+1.71%)
As of 05:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • Takeda Pharmaceutical Company Limited recently announced superior Phase 3 head-to-head results for zasocitinib, an investigational oral tyrosine kinase 2 inhibitor for moderate-to-severe plaque psoriasis, demonstrating better skin clearance than the existing standard of care, deucravacitinib, which strengthens the company's immunology pipeline and potential for market leadership in this therapeutic area.
  • The company reported a significant earnings beat in its most recent quarterly results, delivering $0.95 in earnings per share compared to analyst consensus estimates of $0.41, alongside revenue of $7.50 billion that exceeded expectations of $7.13 billion, indicating strong operational performance and profitability that supports the current stock price of $18.34.
  • Takeda Pharmaceutical Company Limited has expanded its global vaccine footprint by partnering with Dr. Reddy's to distribute the Qdenga dengue vaccine in India, marking the launch of the country's first dengue vaccine and providing a new revenue stream in a high-growth emerging market with significant unmet medical needs.

Cons of Takeda Pharmaceutical

  • Zacks Research recently downgraded Takeda Pharmaceutical Company Limited from a "strong-buy" to a "hold" rating, signaling that analysts believe the stock's recent performance may have already priced in much of the positive news, reducing the potential for near-term upside relative to other opportunities.
  • Corporate insiders have been actively selling their shares, with over 627,000 shares sold in the last 90 days valued at approximately $11 million, including significant reductions in positions by executives such as Andrew Plump and Lauren Duprey, which may indicate a lack of internal conviction in the current valuation.
  • The company faces significant financial risk from ongoing legal matters, as noted in recent reports highlighting a net loss of 152.1 billion yen despite strong core operating profits, with future performance heavily dependent on the outcome of a US jury verdict that could impact the bottom line.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$59.34 billion
P/E Ratio
11.02
Consensus Rating
Moderate Buy
Consensus Price Target
N/A
Volume
4.68 million shares
Average Volume
2.55 million shares
Today's Range
$18.57
▼
$19.04
50-Day Range
$17.03
▼
$19.06
52-Week Range
$12.99
▼
$19.10
Dividend Yield
2.60%
Natera stock logo

32. Natera NASDAQ:NTRA

$394.75 -0.90 (-0.23%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$392.02 -2.74 (-0.69%)
As of 05:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Market Capitalization
$57.03 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$368.69 (-6.6% Downside)
Volume
1.05 million shares
Average Volume
1.95 million shares
Today's Range
$391.28
▼
$405.11
50-Day Range
$265.38
▼
$425.64
52-Week Range
$172.82
▼
$437.41
Dividend Yield
N/A
Cardinal Health stock logo

33. Cardinal Health NYSE:CAH

$247.32 +7.60 (+3.17%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$248.00 +0.67 (+0.27%)
As of 05:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • Cardinal Health, Inc. recently extended its pharmaceutical distribution agreement with CVS Health through June 2032, a move that reduces revenue uncertainty by securing a major customer relationship for the long term and was met with a positive market reaction as the stock rose on the news.
  • The company demonstrated strong earnings momentum by beating consensus estimates in its most recent quarter, reporting earnings per share of $2.91 against an expected $2.42, while also reaffirming its fiscal 2027 guidance of $12.40 to $12.60 per share, which signals management confidence in continued profit growth.
  • Wall Street analysts maintain a "Moderate Buy" consensus rating with a price target of $266.56, which represents significant upside potential from the current stock price of $238.23, reflecting institutional belief in the company's future performance.

Cons of Cardinal Health

  • There is a notable trend of insider selling, with the CEO and other executives selling over 210,000 shares worth approximately $49.6 million in the last quarter, which can signal that company insiders may see the stock as overvalued or are seeking to diversify their personal wealth.
  • Despite strong earnings, the company reported a negative return on equity of 98.53% and a thin net margin of 0.67% in the most recent quarter, indicating that while revenue is high, the profitability relative to shareholder equity and total sales is very low.
  • Short interest has been increasing recently, with shares shorted rising to 7,369,236 in the latest reporting period, a 10.5% month-over-month increase, suggesting that a growing number of traders are betting against the stock's price appreciation.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$55.51 billion
P/E Ratio
34.21
Consensus Rating
Moderate Buy
Consensus Price Target
$266.56 (+7.8% Upside)
Volume
1.97 million shares
Average Volume
1.83 million shares
Today's Range
$240.76
▼
$247.93
50-Day Range
$220.12
▼
$248.88
52-Week Range
$152.46
▼
$258.30
Dividend Yield
0.86%
Becton, Dickinson and Company stock logo

34. Becton, Dickinson and Company NYSE:BDX

$188.83 +1.46 (+0.78%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$189.68 +0.85 (+0.45%)
As of 04:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • Becton, Dickinson and Company has announced a landmark partnership with the U.S. Government to invest $19 billion in domestic manufacturing, a move designed to secure the healthcare supply chain and achieve tariff relief, which provides significant strategic stability and potential cost advantages for the company.
  • The stock is currently trading at $180.00, which is below the average analyst price target of $187.67, suggesting that the market may be undervaluing the company relative to Wall Street's expectations for its future performance.
  • Recent positive nine-month results from the AGILITY trial for the Revello device demonstrate high vessel patency and low reintervention rates, strengthening the company's leadership in peripheral vascular innovation and supporting the growth of its Interventional segment.

Cons of Becton, Dickinson and Company

  • The company has a high price-to-earnings ratio of 54.22, which is significantly above the market average, implying that investors are paying a premium for earnings that may not be sustainable if growth slows or margins compress.
  • Insiders have sold a total of 6,906 shares valued at $1,265,855 in the last 90 days, including sales by CEO Thomas E. Polen, Jr. and EVP Michael Feld, which may signal a lack of confidence in the stock's near-term upside from those closest to the company.
  • The consensus rating from analysts is "Hold," with nine analysts giving a Hold rating compared to eight Buy ratings, suggesting that the stock is fairly valued and lacks the strong momentum or upside potential that would justify an aggressive buy recommendation.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$51.63 billion
P/E Ratio
14.41
Consensus Rating
Hold
Consensus Price Target
$185.07 (-2.0% Downside)
Volume
1.65 million shares
Average Volume
1.81 million shares
Today's Range
$186.04
▼
$189.68
50-Day Range
$176.18
▼
$191.95
52-Week Range
$127.59
▼
$193.07
Dividend Yield
2.24%
Humana stock logo

35. Humana NYSE:HUM

$428.50 +8.12 (+1.93%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$427.25 -1.25 (-0.29%)
As of 05:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • Humana Inc. recently announced a strategic joint venture with BlackRock to manage nearly 150 CenterWell Senior Primary Care clinics, a deal valued at $2.8 billion that provides the company with significant capital and an asset-light structure to expand its senior-focused care network while easing balance sheet liabilities.
  • The company reported that 95% of its members are now enrolled in Medicare Advantage plans rated four stars or higher for 2027, a substantial improvement that supports future government bonus payments and enhanced benefits, with the largest financial benefits expected to be realized in 2028.
  • Humana Inc. shares are currently trading at $428.50, reflecting a strong upward trend from the 52-week low of $163.11, driven by recent analyst upgrades including Mizuho raising its price target to $495 and Raymond James upgrading the stock to outperform with a $520 target.

Cons of Humana

  • The stock carries a high valuation with a P/E ratio of 40.54, which may limit further upside potential and increase sensitivity to any future earnings disappointments or negative news in the managed care sector.
  • Despite recent positive developments, the consensus rating from analysts remains a Hold with an average price target of $403.91, which is below the current stock price of $428.50, suggesting that many analysts believe the stock is currently overvalued relative to its fair value.
  • Humana Inc. reported a net margin of only 0.88% in its most recent quarter, indicating that the company retains a very small portion of its revenue as profit, which can make earnings volatile and sensitive to changes in medical costs or regulatory environments.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$50.48 billion
P/E Ratio
40.54
Consensus Rating
Moderate Buy
Consensus Price Target
$453.30 (+5.8% Upside)
Volume
1.11 million shares
Average Volume
1.60 million shares
Today's Range
$421.61
▼
$432.15
50-Day Range
$367.98
▼
$432.24
52-Week Range
$163.11
▼
$456.50
Dividend Yield
0.82%
argenex stock logo

36. argenex NASDAQ:ARGX

$818.30 +15.66 (+1.95%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$837.42 +19.12 (+2.34%)
As of 04:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenex

Pros of argenex

  • argenx SE successfully met the primary endpoint in its Phase II celiac disease study for its candidate drug FB102, a development that paves the way for late-stage development and provides a new growth driver for the company's pipeline.
  • The company demonstrated strong financial performance in its most recent quarterly report, beating consensus estimates with an earnings per share of $7.32 compared to the expected $5.86, while also exceeding revenue forecasts with $1.54 billion in sales against an estimate of $1.45 billion.
  • argenx SE maintains a favorable valuation profile with a P/E/G ratio of 0.86, which suggests that its growth rate is high relative to its current price-to-earnings multiple, potentially offering attractive value to growth-oriented investors.

Cons of argenex

  • argenx SE recently discontinued its late-stage Phase 3 trial for Vyvgart in Sjögren's disease due to a futility finding, a significant setback that caused the stock to tumble nearly 15% and raises concerns about the company's ability to expand its lead product into new indications.
  • Several major financial institutions have recently lowered their price targets for the stock, including Oppenheimer cutting its target to $1,038.00 and Robert W. Baird reducing its target to $823.00, reflecting a more cautious outlook on the company's near-term prospects.
  • The stock has experienced significant volatility, including a gap down of $97.21 on October 8, 2026, which highlights the high risk associated with the company's pipeline developments and market sentiment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$50.21 billion
P/E Ratio
31.42
Consensus Rating
Moderate Buy
Consensus Price Target
$1,151.95 (+40.8% Upside)
Volume
464,115 shares
Average Volume
409,606 shares
Today's Range
$803.00
▼
$835.31
50-Day Range
$802.64
▼
$1,058.90
52-Week Range
$661.85
▼
$1,072.75
Dividend Yield
N/A
Edwards Lifesciences stock logo

37. Edwards Lifesciences NYSE:EW

$86.47 +1.20 (+1.40%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$87.47 +1.00 (+1.16%)
As of 04:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • Edwards Lifesciences Co. recently secured FDA approval for the AUTUS Size-Adjustable Valve, which is the first surgical pulmonary valve designed specifically for pediatric patients with congenital heart disease, expanding the company's addressable market into a new demographic that previously lacked a durable, size-adjustable solution.
  • The company demonstrated strong financial performance in its most recent quarterly report, beating consensus estimates with earnings per share of $0.78 compared to the expected $0.74, while also exceeding revenue expectations with $1.74 billion in sales, indicating robust demand for its structural heart disease therapies.
  • Analyst sentiment remains positive with a consensus rating of Moderate Buy and an average target price of $100.27, which suggests significant upside potential from the current stock price of $85.62, reflecting confidence in the company's long-term growth trajectory and product pipeline.

Cons of Edwards Lifesciences

  • The company is trading at a premium valuation with a price-to-earnings ratio of 49.21, which is significantly higher than many peers in the healthcare sector, meaning investors are paying a high price for each dollar of earnings and may face downside risk if growth slows or expectations are not met.
  • Corporate insiders have been consistently selling shares, with multiple vice presidents and the CFO executing sales transactions in recent months, which can signal a lack of confidence in the stock's near-term upside or a desire to diversify personal holdings at current price levels.
  • Short interest in the stock has increased in recent months, with shares shorted rising to over 9 million shares, indicating that a portion of the market is betting against the company's performance, which could lead to volatility if short sellers continue to add to their positions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$49.10 billion
P/E Ratio
49.69
Consensus Rating
Moderate Buy
Consensus Price Target
$100.27 (+16.0% Upside)
Volume
4.04 million shares
Average Volume
3.79 million shares
Today's Range
$84.83
▼
$86.62
50-Day Range
$84.18
▼
$93.59
52-Week Range
$72.40
▼
$96.29
Dividend Yield
N/A
Veeva Systems stock logo

38. Veeva Systems NYSE:VEEV

$297.17 -4.46 (-1.48%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$290.74 -6.43 (-2.16%)
As of 04:45 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. More about Veeva Systems

Pros of Veeva Systems

  • Veeva Systems Inc. recently announced that its Data Quality System (DQS) has aggregated and cleaned data for more than 1 million subjects across over 1,000 clinical studies, a development that significantly enhances the company's value proposition by automating data reconciliation and saving clinical teams substantial time and cost, thereby strengthening its position in the clinical data management market.
  • The company reported strong financial performance in its most recent quarter, with revenue of $927.96 million, which exceeded the consensus estimate of $905.38 million and represented a 17.6% year-over-year increase, demonstrating robust demand for its cloud-based software solutions in the life sciences industry.
  • Veeva Systems Inc. has set its full-year 2027 earnings per share guidance at $9.21, which is significantly higher than the consensus estimate of $8.58, indicating management's confidence in continued growth and the company's ability to deliver above-market returns to shareholders.

Cons of Veeva Systems

  • The company's price-to-earnings ratio is 46.40, which is relatively high compared to the broader market, suggesting that the stock may be overvalued and that investors are paying a premium for its growth, which could lead to significant downside if earnings growth slows or fails to meet expectations.
  • Short interest in Veeva Systems Inc. has been increasing, with the number of shares shorted rising to 4,964,067 in the most recent reporting period, indicating that a significant number of investors are betting against the stock, which could signal concerns about the company's future performance or valuation.
  • Several institutional investors have reduced their holdings in Veeva Systems Inc. in the most recent quarter, including Rockland Trust Co., which lowered its position by 2.3%, and Bright Rock Capital Management LLC, which sold 43,000 shares, suggesting that some large investors are taking profits or re-evaluating their exposure to the stock.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$48.84 billion
P/E Ratio
48.73
Consensus Rating
Moderate Buy
Consensus Price Target
$284.88 (-4.1% Downside)
Volume
1.24 million shares
Average Volume
1.59 million shares
Today's Range
$293.66
▼
$301.50
50-Day Range
$217.52
▼
$302.02
52-Week Range
$148.05
▼
$309.32
Dividend Yield
N/A
Agilent Technologies stock logo

39. Agilent Technologies NYSE:A

$173.90 +2.30 (+1.34%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$174.00 +0.11 (+0.06%)
As of 04:39 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • Agilent Technologies, Inc. recently reported strong third-quarter results on August 26, 2026, beating analyst expectations with earnings per share of $1.62 compared to a consensus estimate of $1.49, while also exceeding revenue forecasts with $1.88 billion in sales against an expected $1.84 billion, demonstrating robust operational performance and demand for its laboratory solutions.
  • The company has raised its full-year 2026 guidance to a range of $6.180 to $6.210 in earnings per share, which is above the previous consensus estimate of $6.060, signaling management confidence in sustained growth and providing a clear upward trajectory for shareholder returns over the coming months.
  • Agilent Technologies, Inc. is currently trading at $169.07, a level that remains below the recent price target of $195.00 set by Barclays, which suggests potential upside of approximately 15% for investors who believe the market has not yet fully priced in the company's recent earnings beats and raised guidance.

Cons of Agilent Technologies

  • Despite recent positive news, Wall Street Zen downgraded Agilent Technologies, Inc. from a "buy" to a "hold" rating in early October 2026, suggesting that some analysts believe the stock's recent rally may have already priced in most of the good news, limiting further short-term upside potential.
  • The company's current price-to-earnings ratio stands at 33.28, which is relatively high compared to many industrial peers, meaning investors are paying a premium for earnings that may not be sustainable if the broader economic environment slows down or if competition intensifies in the life sciences tools sector.
  • Short interest in the stock has been fluctuating, with shares shorted increasing to 5,078,629 in the most recent reporting period as of September 15, 2026, indicating that a portion of the market remains skeptical about the stock's valuation or future performance despite the recent earnings beats.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$48.38 billion
P/E Ratio
28.32
Consensus Rating
Moderate Buy
Consensus Price Target
$173.65 (-0.1% Downside)
Volume
2.37 million shares
Average Volume
2.55 million shares
Today's Range
$171.67
▼
$175.54
50-Day Range
$141.35
▼
$175.42
52-Week Range
$108.35
▼
$177.05
Dividend Yield
0.59%
Teva Pharmaceutical Industries stock logo

40. Teva Pharmaceutical Industries NYSE:TEVA

$40.83 -0.42 (-1.02%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$40.89 +0.07 (+0.16%)
As of 05:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Market Capitalization
$48.07 billion
P/E Ratio
68.05
Consensus Rating
Moderate Buy
Consensus Price Target
$45.50 (+11.4% Upside)
Volume
10.27 million shares
Average Volume
6.00 million shares
Today's Range
$40.71
▼
$41.87
50-Day Range
$34.76
▼
$41.22
52-Week Range
$18.83
▼
$42.02
Dividend Yield
N/A
Medline stock logo

41. Medline NASDAQ:MDLN

$35.93 +0.23 (+0.64%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$36.02 +0.09 (+0.24%)
As of 04:52 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Our mission is to make healthcare run better by delivering improved clinical, financial, and operational outcomes. We are the largest provider of medical-surgical (“med-surg”) products and supply chain solutions serving all points of care, based on total net sales of med-surg products. We deliver mission-critical products used daily across the full range of care settings, from hospitals and surgery centers to physician offices and post-acute facilities. Through our two segments, Medline Brand and Supply Chain Solutions, we offer approximately 335,000 med-surg products, including surgical and procedural kits, gloves and protective apparel, urological and incontinence care, wound care, and consumable lab and diagnostics products. We hold the leading position across several of our end markets and many of our key product families. We distribute these products through our expansive network of 69 global distribution facilities, spanning over 29 million square feet of warehouse space, and our owned fleet of over 2,000 MedTrans trucks, enabling us to provide next-day delivery to 95% of our U.S. customers. Our integrated business model and customer-centric culture drives lower costs and better value for our stakeholders. This is the foundation for our durable recurring revenue base, with our net sales having grown every year since inception of the Company at a compound annual growth rate (“CAGR”) of 18%. --- We were founded in 1966 as a med-surg product manufacturer serving the hospital and nursing home sites of care. Through our deep engagement with customers, we recognized a significant gap in the market—our customers were underserved by a fragmented supplier base and faced challenges navigating a complex supply chain. We identified their need for a supply chain partner that was fully integrated, cost-effective, high-quality, and resilient. Our vision was to create a differentiated model that solved these pain points through an integrated company that combined both manufacturing and distribution capabilities and would become a trusted partner to our customers. Twenty-eight years ago, we began augmenting our platform to bring this vision to life: we invested in our distribution capabilities, continued to expand our product portfolio, and adopted the Prime Vendor model. This enabled us to serve a more diverse customer base across multiple end markets, while lowering costs and delivering superior service levels. As a result, Medline is now the largest provider of med-surg products and supply chain solutions serving all points of care, based on total net sales of med-surg products. The combination of our expansive product portfolio and our differentiated supply chain creates a force multiplier for our business. Our Medline Brand segment offers approximately 190,000 products, including those manufactured in our 33 facilities, as well as those sourced from our more than 500 global partners. Our Supply Chain Solutions segment offers approximately 145,000 third-party products and provides customized supply chain optimization services. Our entire product portfolio across our segments is supported by differentiated logistics capabilities and a dedicated and tenured U.S. commercial team of approximately 3,800 people. These capabilities and our compelling value proposition allow us to serve as a long-term strategic partner to our customers and expand the scope of our relationships over time. Our Prime Vendor relationships demonstrate our role as a trusted partner to our customers. In these relationships, we enter into long-term agreements to act as the consolidated distributor and logistics provider for these customers’ med-surg product needs. These partnerships give us visibility into our customers’ purchasing behaviors and demand dynamics, which allows us to anticipate their needs and deliver industry-leading service levels. As these relationships mature, we believe customers increasingly choose Medline Brand products for their superior value. Our Prime Vendor model is reinforced by the flywheel effect within our business where we drive cost savings for Prime Vendor customers, which, over time, supports incremental purchasing of our Medline Brand products and increases our scale. This dynamic allows us to drive further efficiencies by offering superior or similar quality to third-party products at a more cost-effective price. Due to the higher margin we earn on Medline Brand products compared to sales of comparable third-party products, we are able to reinvest in customer value while increasing our profitability. --- Since our founding, we have invested in building a unique customer-centric culture with an entrepreneurial spirit. Our employees are committed to deeply understanding how our customers operate, what challenges they face, and how Medline can better support them. They also understand that relationships are rooted in trust and that we must earn the right to serve our customers every day. We focus on problem solving across the continuum of care and we deploy a team of dedicated customer success representatives to learn the complex needs of our customers. Our creative and collaborative culture consistently earns Medline recognition as a preferred employer, including Newsweek’s Greatest Workplaces, Forbes’ America’s Best Large Employers, and a Chicago Tribune Top Workplace. We have grown our net sales every year by retaining existing customers while gaining share with new and existing customers, with CAGRs of 18% since our founding and approximately 14% over the past 10 years. Notably, nearly 90% of our growth during the past 10 years has been organic. Our product portfolio predominantly consists of consumables, such that approximately 90% of our Medline Brand net sales were recurring for the year ended December 31, 2024. Our business is uniquely resilient during market downturns, as evidenced by our growth through every recession since our founding and during global healthcare crises. For example, our net sales grew at approximately 17% during the 2008-2009 financial crisis and at approximately 11% CAGR during the 2020-2022 COVID-19 pandemic. Not only does our business have a strong track record of results, but we also see significant runway for future sales and earnings growth. We are positioned to grow with our customers as healthcare utilization increases, as they build and acquire new sites, and as they further consolidate med-surg spend with Medline. In addition, we intend to further extend our leading position by adding new Prime Vendor relationships, increasing the number of non-Prime Vendor customers that choose Medline Brand, continuing our channel expansion, developing new products, executing on selective M&A opportunities, and scaling our international footprint. For the nine months ended September 27, 2025, we generated net sales of $20.6 billion, net income of $1.0 billion, and Adjusted EBITDA of $2.7 billion, representing a net income margin of 4.7% and an Adjusted EBITDA Margin of 12.9%. During that period, 48.4% of total net sales and 81.2% of Segment Adjusted EBITDA were generated from our Medline Brand segment, while 51.6% of total net sales and 18.8% of Segment Adjusted EBITDA were generated from our Supply Chain Solutions segment. For the year ended December 31, 2024, we generated net sales of $25.5 billion, net income of $1.2 billion, and Adjusted EBITDA of $3.4 billion, representing a net income margin of 4.7% and an Adjusted EBITDA Margin of 13.2%. During that period, 49.1% of total net sales and 83.5% of Segment Adjusted EBITDA were generated from our Medline Brand segment, while 50.9% of total net sales and 16.5% of Segment Adjusted EBITDA were generated from our Supply Chain Solutions segment. Our principal executive offices are located in Northfield, Illinois.

Market Capitalization
$46.94 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$46.81 (+30.3% Upside)
Volume
4.64 million shares
Average Volume
9.43 million shares
Today's Range
$35.35
▼
$35.98
50-Day Range
$31.64
▼
$36.59
52-Week Range
$31.49
▼
$50.88
Dividend Yield
N/A
IQVIA stock logo

42. IQVIA NYSE:IQV

$262.31 +1.63 (+0.63%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$261.90 -0.42 (-0.16%)
As of 04:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • IQVIA Holdings Inc. recently launched IQVIA Life Science Models, a suite of purpose-built models designed to help life sciences companies predict clinical trial outcomes, leveraging the company's proprietary expert content and deep domain knowledge to enhance its competitive position in the healthcare analytics sector.
  • Analyst sentiment has shifted significantly in favor of the stock, with UBS Group upgrading IQVIA Holdings Inc. to a "strong-buy" rating and Royal Bank of Canada raising its price target from $247.00 to $319.00, indicating strong institutional confidence in the company's future performance and potential for upside.
  • The company demonstrated strong financial execution in its most recent quarterly report, posting earnings per share of $3.15, which exceeded the consensus estimate of $3.03, while revenue reached $4.37 billion, surpassing the expected $4.30 billion and reflecting an 8.7% year-over-year growth rate.

Cons of IQVIA

  • IQVIA Holdings Inc. was recently fined $7.8 million for failing to properly anonymize health data, which poses a regulatory and reputational risk that could impact the company's ability to handle sensitive healthcare information and may lead to increased compliance costs.
  • The company carries a significant debt burden, with a debt-to-equity ratio of 2.18 and net debt of $14.1 billion, which could limit its financial flexibility and increase vulnerability to rising interest rates or economic downturns.
  • Insider selling has been notable, with several executives, including W. Richard Staub and Eric Sherbet, selling thousands of shares in recent months, which may signal a lack of confidence in the stock's near-term performance or a desire to diversify personal holdings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$42.91 billion
P/E Ratio
22.95
Consensus Rating
Moderate Buy
Consensus Price Target
$276.00 (+5.2% Upside)
Volume
1.12 million shares
Average Volume
1.59 million shares
Today's Range
$260.82
▼
$266.66
50-Day Range
$232.41
▼
$275.38
52-Week Range
$154.50
▼
$277.40
Dividend Yield
N/A
Waters stock logo

43. Waters NYSE:WAT

$437.58 +8.41 (+1.96%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$438.15 +0.57 (+0.13%)
As of 04:23 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

Market Capitalization
$42.17 billion
P/E Ratio
109.12
Consensus Rating
Moderate Buy
Consensus Price Target
$443.79 (+1.4% Upside)
Volume
901,435 shares
Average Volume
849,613 shares
Today's Range
$429.90
▼
$441.89
50-Day Range
$399.62
▼
$443.80
52-Week Range
$282.77
▼
$454.54
Dividend Yield
N/A
IDEXX Laboratories stock logo

44. IDEXX Laboratories NASDAQ:IDXX

$529.01 +8.70 (+1.67%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$535.64 +6.63 (+1.25%)
As of 04:52 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • IDEXX Laboratories, Inc. recently demonstrated strong fundamental performance by beating analyst expectations in its most recent earnings report, posting earnings per share of $4.27 against a consensus estimate of $3.94, which indicates the company is generating higher profits than the market anticipated.
  • The company has shown consistent revenue growth, with the most recent quarter seeing revenue increase by 9.7% on a year-over-year basis, suggesting that demand for its veterinary diagnostic products and services remains robust and is expanding.
  • IDEXX Laboratories, Inc. currently trades at a stock price of $529.01, which is significantly below the average analyst price target of $747.00, implying that the stock may be undervalued relative to the long-term growth potential projected by financial experts.

Cons of IDEXX Laboratories

  • The stock is trading at a price-to-earnings ratio of 37.20, which is considered elevated, meaning investors are paying a premium for each dollar of earnings, and this high valuation leaves little room for error if future growth slows down.
  • Recent insider activity has been predominantly negative, with multiple executives and directors, including the CEO and EVPs, selling significant blocks of shares in early 2026, which can signal a lack of confidence in the stock's near-term upside from those closest to the company.
  • IDEXX Laboratories, Inc. has a beta of 1.55, a measure of volatility that indicates the stock is 55% more volatile than the overall market, meaning it is likely to experience larger price swings in both directions compared to the broader economy.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$40.99 billion
P/E Ratio
36.59
Consensus Rating
Moderate Buy
Consensus Price Target
$747.00 (+41.2% Upside)
Volume
824,386 shares
Average Volume
504,844 shares
Today's Range
$518.84
▼
$529.63
50-Day Range
$504.70
▼
$595.76
52-Week Range
$500.61
▼
$769.98
Dividend Yield
N/A
Illumina stock logo

45. Illumina NASDAQ:ILMN

$271.76 +0.59 (+0.22%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$272.32 +0.56 (+0.20%)
As of 05:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. More about Illumina

Pros of Illumina

  • Illumina, Inc. recently released SpliceAI2, a new genomic AI model that helps researchers identify disease-relevant splice variants, which is a significant advancement for rare disease research and drug discovery that positions the company at the forefront of AI-driven genomics.
  • The company's stock is currently trading at $264.57, reflecting a strong upward trend from its 52-week low of $88.00, driven by its recent addition to the S&P 500 index which typically attracts significant demand from index-tracking funds.
  • Analysts from RBC Capital Markets have characterized Illumina's clinical sequencing revenue as a durable mid-teens growth opportunity, suggesting that the company has a stable and expanding revenue stream from a high-demand sector.

Cons of Illumina

  • Despite the recent rally, the consensus rating from eighteen brokerages remains "Hold" with an average 12-month price objective of $219.69, which is significantly below the current stock price of $264.57, suggesting that the stock may be overvalued relative to analyst expectations.
  • Insider selling has been substantial, with Director Keith Meister selling over 119,000 shares in September 2026 alone, and insiders collectively selling over 2 million shares worth approximately $436 million in the last three months, which may signal a lack of confidence from those closest to the company.
  • Barclays has maintained an "underweight" rating on Illumina, Inc. with a price target of $200, arguing that current expectations and valuation have outpaced near-term fundamentals, indicating that the stock's recent gains may not be sustainable.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$40.95 billion
P/E Ratio
50.70
Consensus Rating
Hold
Consensus Price Target
$225.94 (-16.9% Downside)
Volume
2.12 million shares
Average Volume
4.47 million shares
Today's Range
$267.23
▼
$276.55
50-Day Range
$187.96
▼
$293.69
52-Week Range
$90.10
▼
$309.35
Dividend Yield
N/A
Revolution Medicines stock logo

46. Revolution Medicines NASDAQ:RVMD

$193.52 +5.08 (+2.70%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$193.22 -0.31 (-0.16%)
As of 04:39 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Market Capitalization
$40.39 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$234.81 (+21.3% Upside)
Volume
2.46 million shares
Average Volume
2.41 million shares
Today's Range
$185.88
▼
$197.00
50-Day Range
$188.12
▼
$221.15
52-Week Range
$47.45
▼
$224.31
Dividend Yield
N/A
BeOne Medicines stock logo

47. BeOne Medicines NASDAQ:ONC

$351.48 +2.40 (+0.69%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$354.98 +3.50 (+1.00%)
As of 04:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Market Capitalization
$38.32 billion
P/E Ratio
61.46
Consensus Rating
Buy
Consensus Price Target
$404.93 (+15.2% Upside)
Volume
361,611 shares
Average Volume
368,405 shares
Today's Range
$344.94
▼
$355.76
50-Day Range
$329.80
▼
$376.86
52-Week Range
$253.95
▼
$385.22
Dividend Yield
N/A
Centene stock logo

48. Centene NYSE:CNC

$70.07 +1.21 (+1.75%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$70.50 +0.43 (+0.61%)
As of 04:52 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. More about Centene

Pros of Centene

  • Centene Co. recently demonstrated strong financial performance by reporting an earnings per share of $2.51 for the quarter ended July 27, 2026, which significantly exceeded the analyst consensus estimate of $1.09, indicating a substantial beat that often signals improved operational efficiency and profitability to the market.
  • The company's stock is currently trading at $64.49, which is below the average analyst price target of $70.05, suggesting that the stock may be undervalued relative to Wall Street's expectations for its future growth and earnings potential.
  • Centene Co. is expanding its primary care access through a new partnership with Marathon Health, which will provide eligible members in Indiana and Missouri with $0 primary care visits, lab services, and virtual care beginning in 2027, potentially enhancing member retention and reducing long-term healthcare costs.

Cons of Centene

  • Zacks Research recently downgraded Centene Co. from a "strong-buy" rating to a "hold" rating, reflecting concerns about the sustainability of its earnings recovery and the potential for future earnings dips, as analysts anticipate a double-digit profit decline in the upcoming quarter.
  • The company is facing elevated costs in its Medicare Advantage segment, which has pressured plan economics and led to a narrowing of its 2027 footprint, indicating that cost management remains a significant challenge that could impact future profitability and growth prospects.
  • Centene Co. has a high short interest, with 14,134,355 shares shorted as of September 15, 2026, representing 2.87% of the float, which suggests that a significant portion of investors are betting against the stock, potentially leading to increased volatility and downward price pressure.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$34.02 billion
P/E Ratio
N/A
Consensus Rating
Hold
Consensus Price Target
$70.05 (-0.0% Downside)
Volume
4.92 million shares
Average Volume
4.80 million shares
Today's Range
$68.51
▼
$70.37
50-Day Range
$60.95
▼
$70.07
52-Week Range
$31.63
▼
$70.37
Dividend Yield
N/A
Biogen stock logo

49. Biogen NASDAQ:BIIB

$232.83 +3.93 (+1.72%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$235.24 +2.41 (+1.03%)
As of 04:52 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. More about Biogen

Pros of Biogen

  • Biogen Inc. shares are currently trading at $222.15, a level that sits just below the recent 52-week high of $230.49, indicating strong recent momentum and investor confidence in the company's trajectory.
  • The company demonstrated strong fundamental performance in its most recent earnings report on July 29, 2026, where it reported earnings per share of $3.60, significantly beating the consensus estimate of $2.94, while also exceeding revenue expectations with $2.74 billion in sales.
  • Wall Street analysts maintain a positive outlook, with the current consensus rating standing at "Moderate Buy" and an average price target of $230.14, suggesting that many experts believe the stock still has room to grow from its current price.

Cons of Biogen

  • The stock carries a high price-to-earnings ratio of 39.32, meaning investors are paying nearly 40 times the company's current earnings for each share, which may be considered expensive compared to other sectors or if future earnings growth does not accelerate.
  • Short interest in the stock has been increasing recently, with the number of shares shorted rising to 5,817,797 as of September 15, 2026, indicating that a growing number of traders are betting against the stock's future performance.
  • Biogen Inc. does not currently pay a dividend, as indicated by a dividend yield of 0.00%, which may be a drawback for income-focused investors who prefer regular cash payments in addition to potential capital appreciation.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.82 billion
P/E Ratio
41.21
Consensus Rating
Moderate Buy
Consensus Price Target
$236.04 (+1.4% Upside)
Volume
1.95 million shares
Average Volume
1.21 million shares
Today's Range
$228.00
▼
$234.20
50-Day Range
$203.89
▼
$232.83
52-Week Range
$138.00
▼
$238.24
Dividend Yield
N/A
ResMed stock logo

50. ResMed NYSE:RMD

$235.55 +0.51 (+0.22%)
Closing price 10/14/2026 03:59 PM Eastern
Extended Trading
$234.02 -1.53 (-0.65%)
As of 04:51 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More about ResMed

Pros of ResMed

  • ResMed Inc. demonstrated strong fundamental performance in its most recent quarterly report on August 6, 2026, where it reported earnings per share of $2.95, beating the consensus estimate of $2.89 by $0.06. This beat, combined with revenue of $1.46 billion that met analyst expectations and grew 8.6% year-over-year, indicates that the company is successfully executing its growth strategy and maintaining profitability, which is a key driver for long-term shareholder value.
  • The company recently increased its quarterly dividend to $0.66 per share, up from the previous $0.60, representing a 10% increase. This move, paid on September 24, 2026, signals management's confidence in the company's cash flow generation and commitment to returning capital to shareholders, providing a growing income stream with a current dividend yield of 1.12%.
  • ResMed Inc. maintains a conservative balance sheet with a debt-to-equity ratio of only 0.06 and a current ratio of 3.10, indicating strong liquidity and minimal financial risk. This financial stability allows the company to navigate economic uncertainties more effectively than peers with higher leverage, protecting shareholder equity during market downturns.

Cons of ResMed

  • CEO Michael Farrell has engaged in consistent stock sales under a Rule 10b5-1 trading plan, selling 4,991 shares on October 7, 2026, at an average price of $226.33. This is part of a pattern of monthly sales, including transactions in September, August, and July 2026, which may signal that insiders are taking advantage of current valuations to reduce their personal exposure, potentially indicating a lack of confidence in further short-term price appreciation.
  • The consensus rating from sell-side analysts has shifted to "Hold" as of September 26, 2026, with a consensus price target of $241.69. This is a significant downgrade from the "Moderate Buy" ratings and higher price targets (such as $299.27 in early 2026) seen earlier in the year, suggesting that analysts have become more cautious about the stock's upside potential and are less bullish on its future performance.
  • Short interest in ResMed Inc. has been increasing, with shares shorted rising to 12,783,009 as of September 30, 2026, up from 11,881,847 in late May 2026. This growing short interest, representing about 9.14% of the float, indicates that a significant portion of the market is betting against the stock, which could create downward pressure on the share price and increase volatility.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.06 billion
P/E Ratio
21.04
Consensus Rating
Hold
Consensus Price Target
$243.23 (+3.3% Upside)
Volume
991,522 shares
Average Volume
1.14 million shares
Today's Range
$232.76
▼
$237.06
50-Day Range
$211.85
▼
$240.47
52-Week Range
$180.26
▼
$277.67
Dividend Yield
1.12%